Inventor · disambiguated record
Robert V. Tighe, Iii
Also filed as: TIGHE III ROBERT V · TIGHE ROBERT
10 granted patents·10 pending applications·58 citations·filing 2012–2025
89Inventor score
Top patents by PatentIndex Score
20 records- 0196US10716851B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Jul 21, 2020·10 cites·5 claims
- 0296US10350292B1Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Jul 16, 2019·12 cites·28 claims
- 0396US10279039B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·10 cites·20 claims
- 0496US10279038B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·11 cites·16 claims
- 0596US10279040B1Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted May 7, 2019·10 cites·20 claims
- 0695US10434175B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Granted Oct 8, 2019·5 cites·20 claims
- 0787US2024181050A1Agonist antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 0880US12286483B2Method of treating cancer using CD137 antibodies and PD-1 antagonistsCOMPASS THERAPEUTICS LLC·Filed 2023·Granted Apr 29, 2025·0 cites·22 claims
- 0978US2020046833A1Agonist antibodies that bind human cd137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 1075US11752207B2Agonist antibodies that bind human CD137 and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2020·Granted Sep 12, 2023·0 cites·13 claims
- 1170US11718679B2CD137 antibodies and PD-1 antagonists and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Aug 8, 2023·0 cites·28 claims
- 1270US2025313645A1Cd137 antibodies and pd-1 antagonists and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 1357US2023065936A1Compositions and methods for treating cancerTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1453US2024252641A1Compositions and methods for tcr reprogramming using cd70 specific fusion proteinsTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1552US2024117002A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1652US2023069322A1Compositions and methods for gamma delta tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1749US11851497B2CD137 antibodies and tumor antigen-targeting antibodies and uses thereofCOMPASS THERAPEUTICS LLC·Filed 2018·Granted Dec 26, 2023·0 cites·11 claims
- 1841US2019031785A1Multispecific immunomodulatory antigen-binding constructsCOMPASS THERAPEUTICS LLC·Filed 2017·Application pending·0 cites
- 1938US2018318417A1Multispecific immunomodulatory antigen-binding constructsCOMPASS THERAPEUTICS LLC·Filed 2016·Application pending·0 cites
- 2035US2014308294A1Anti-IL-1R1 Inhibitors For Use in CancerSESHIRE ANITA·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert V. Tighe, Iii files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →